Amadix news

“When we had few results, being in very intensive phases in human, capital and financing, finding a motivated team which works in an uncertainty environment, such as that of R&D in our country, was complicated. But without doubt we have that team, and this award is for the whole team, and it encourages us to continue and will do so when difficult times arise again”

Onda Cero Valladolid recognizes the commitment, dedication, and compromise of the society of Valladolid during the first ceremony of the awards in Centro Cultural Miguel Delibes (Valladolid), where Amadix, among other projects, was awarded.

Lucía Reinoso, CFO, collected the award to “Best company” on behalf of Amadix, sharing stage with other personaliti

Rocío Arroyo, researcher, and CEO of Amadix, leads the team that has created an innovative blood-based test that can detect if a healthy person will develop a malignant colon tumour in the future.

As an entrepreneur, Rocío turned her scientific knowledge into a viable business model securing private investors in Castile and Leon to found Amadix.

Amadix is toda

EIC Accelerator is the biggest funding round supported by the European Commission, with a total budget of 637 million euros and more than 90 million euros to be distributed between the 11 Spanish start-ups selected, including Amadix.

To be part of the EIC Accelerator is a big boost for the company and the commercialization of Amadix’ firs product, PREVECOL^® (pr

This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world.

Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix.

As an example: biotech companies in Spain are about 900, and 90% of them are SME and micro-SME, and their product development phases are very long, they need a lot of input of resources. Hence, these companies require very specific instruments of financing.

Despite the pandemic, oncology still being the therapeutic area with the highest level of investigation among AseBio’s partners. Up until 72% of the new cancer treatments are developed thanks to biotechnology and the sector became key, considering that the number of diagnostics decreased due the health crisis according to SEOM’s data.

Amadix’ CEO, Rocío Arr